Theranostic Trials

Thymoma

Adrenal Gland/AdrenocorticalBasket Trials (Multiple Types)Biliary Tract/Gall Bladder/Cholangiocarcinoma (GI)Bladder/Urothelial (GU)Bone MetastasesBrain and Central Nervous System (CNS)BreastCervical (GYN)Colon/Rectal/Anal (GI)Endocrine CancersEndocrine NeoplasiaEsophageal (GI)Gastric/Stomach (GI)Gastrointestinal (GI) (Multiple Types)General Solid Tumors (Multiple Types)GenitoUrinary (GU) (Multiple Types)GEP-NET (NEC)GI Stromal Tumor (GIST)Gynecologic (GYN) (Multiple Types)Head and Neck CancersHepatocellular/Liver (GI)Hodgkins LymphomaInsulinomaKidney/Renal Cell Carcinoma (GU)LeukemiasLungLymphomasMelanoma/Skin CancersMesotheliomaMultiple MyelomaNeuroBlastomaNeuroEndocrine (NEC) (Multiple Types)NeuroEndocrine Carcinoma (NEC)OsteosarcomaOvarianOvarian/Primary Peritoneal (GYN)Pancreatic (GI)Paraganglioma (NEC)Penile (GU)Pheochromocytoma (NEC)PituitaryProstate (GU)Salivary GlandSarcomaSynovial CarcinomaTesticular (GU)ThymomaThyroidUnknown Primary CancersUterine (GYN)Vulvar (GYN)

Study Status

Enrolling
On Hold
Not Enrolling
Unknown

Last Updated: Mon Dec 16 2024

Pharmaceutical Trials (Site Sponsors)

Investigator Trials

Pharmaceutical & Investigator Trials (Non-Site Sponsors)

NCT06086327

Chemokine Receptor CXCR4-targeting PET Imaging for Thymoma

Chemokine receptor CXCR4 was expressed in T cells and CXCR4-targeting molecular imaging- 68Ga-Pentixafor PET/CT could be a promising technique to evaluate the extent of thymoma with higher accuracy. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, distinguish evaluation for thymoma.

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468